{
  "documentMetadata": {
    "title": "Toxic Shock Syndrome (TSS), Staphylococcal",
    "sourceFile": "Toxin_mediated/Toxic Shock Syndrome (TSS), Staphylococcal.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "paragraph",
      "text": "Toxic shock syndrome (TSS) in patient colonized or locally invaded with toxin producing Staphylococcus aureus."
    },
    {
      "type": "list",
      "items": [
        "Includes vaginal (tampon-associated), surgical or traumatic wounds, endometrium, burns.",
        "Can also occur concomitant with local S. aureus necrotizing abscesses in skin, lungs, or elsewhere"
      ]
    },
    {
      "type": "paragraph",
      "text": "In distinction to streptococcal TSS, staphylococcal TSS need not have any overt evidence of infection by the colonizing toxigenic S. aureus."
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "header",
          "level": 2,
          "text": "Definition of TSS:"
        },
        {
          "type": "paragraph",
          "text": "Fever and hypotension, erythroderma (desquamates after a week or more) with evidence of multisystem injury:"
        },
        {
          "type": "list",
          "items": [
            "Nausea/vomiting, diarrhea, renal insufficiency, encephalopathy, ARDS, thrombocytopenia.",
            "There is often reduction in the free serum calcium concentration (mechanism unknown)."
          ]
        }
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Staphylococcus aureus"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "procedure",
      "procedureData": {
        "name": "Aggressive parenteral fluid replacement",
        "indication": "Toxin causes capillary leak"
      }
    },
    {
      "type": "procedure",
      "procedureData": {
        "name": "Examine for and remove any colonized foreign body",
        "notes": "e.g., vaginal tampon, surgical packing"
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "condition": "MSSA",
        "components": [
          {
            "drug": "Nafcillin",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "q4h"
          },
          {
            "drug": "Oxacillin",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "q4h",
            "connector": "or"
          },
          {
            "drug": "Clindamycin",
            "dose": "900 mg",
            "route": "IV",
            "frequency": "q8h",
            "connector": "+"
          },
          {
            "drug": "IVIG",
            "dose": "1 gm/kg day 1, then 0.5 gm/kg days 2 and 3",
            "connector": "+"
          }
        ],
        "notes": "For patients unresponsive to fluids and vasopressors."
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "condition": "MRSA",
        "components": [
          {
            "drug": "Vancomycin",
            "dose": "15-20 mg/kg",
            "route": "IV",
            "frequency": "q8-12h"
          },
          {
            "drug": "Clindamycin",
            "dose": "900 mg",
            "route": "IV",
            "frequency": "q8h",
            "connector": "+"
          }
        ],
        "notes": "To achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator; alternative is trough of 15-20 µg/mL). For either MSSA or MRSA, If unresponsive to fluids and vasopressors, consider adding IVIG 1 gm/kg day 1, then 0.5 gm/kg days 2 and 3"
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "condition": "MSSA",
        "components": [
          {
            "drug": "Cefazolin",
            "dose": "1-2 gm",
            "route": "IV",
            "frequency": "q8h"
          },
          {
            "drug": "Clindamycin",
            "dose": "900 mg",
            "route": "IV",
            "frequency": "q8h",
            "connector": "+"
          }
        ],
        "notes": "Can consider adding IVIG 1 gm/kg day 1, then 0.5 gm/kg days 2 and 3 for patients unresponsive to fluids and vasopressors."
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "condition": "MRSA",
        "components": [
          {
            "drug": "Vancomycin",
            "dose": "15-20 mg/kg",
            "route": "IV",
            "frequency": "q8-12h"
          },
          {
            "drug": "Daptomycin",
            "dose": "6 mg/kg",
            "route": "IV",
            "frequency": "q24h",
            "connector": "or"
          },
          {
            "drug": "Clindamycin",
            "dose": "900 mg",
            "route": "IV",
            "frequency": "q8h",
            "connector": "+"
          }
        ],
        "notes": "To achieve preferred target AUC24 400-600 µg/mL x hr [see vancomycin AUC dosing calculator; alternative is trough of 15-20 µg/mL]. Can consider adding IVIG 1 gm/kg day 1, then 0.5 gm/kg days 2 and 3 for patients unresponsive to fluids and vasopressors."
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "condition": "If unable to use clindamycin",
        "components": [
          {
            "drug": "Linezolid"
          }
        ],
        "notes": "To suppress toxin production"
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Ability of IVIG to neutralize S. aureus TSS toxin less than ability to neutralize S. pyogenes TSST (Clin Infect Dis 38:836, 2004); IVIG efficacy unproven.",
        "Adjunctive clindamycin used to inhibit bacterial production of TSS toxin.",
        "In vitro, can inhibit toxin production with clindamycin, linezolid, or tedizolid",
        "Support for clinical efficacy of combination therapy with clindamycin limited to poorly-controlled clinical trials and case reports",
        "In retrospective review of patients with necrotizing S. aureus pneumonia, MRSA patients treated with both vanco and clinda, or linezolid, had shorter hospitalizations and a lower relapse rate",
        "No matched controls (Respiration 2011; 81:448)",
        "Despite absence of well-controlled clinical trials, Guidelines support \"consideration\" of clindamycin in addition to standard therapy in patient's with S. aureus, TSS.",
        "Review of use of clindamycin, linezolid, and tedizolid to inhibit toxin production: J Antimicrob Chemother 2019;74:1",
        "Reviews:",
        "Antibiotics (Basel). 2024; 13:96",
        "Lancet Infect Dis 9:281, 2009."
      ]
    }
  ]
}